Availability and approval of cannabis ‐based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation

ConclusionsThere are marked differences between the countries represented in EFIC in the approval and availability of cannabis‐based products for medical use. EFIC countries are encouraged to collaborate with the European Medicines Agency to publish a common document on cannabis‐based medicines. SignificanceThere are striking differences between European countries in the availability of plant‐derived and synthetic cannabinoids and of medical cannabis for pain management and for symptom control in palliative care and in the covering of costs by health insurance companies or state social security systems.
Source: European Journal of Pain - Category: Anesthesiology Authors: Tags: Original Article Source Type: research